Autoimmune Treatment Market
Segments - by Applications (Systemic Autoimmune Diseases [Psoriasis, Rheumatoid Arthritis, Lupus, and Others] and Localized Autoimmune Diseases [Multiple Sclerosis]), Products (Drugs, Diagnostic Equipment, and Therapeutic & Monitoring Equipment), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021-2028
The global autoimmune treatment market size is anticipated to register a significant CAGR during the forecast period, 2021-2028. The growth of the market is attributed to the wide prevalence of autoimmune diseases coupled with the increasing awareness among patients regarding the availability of several alternatives for the treatment of autoimmune diseases. Rising investments for the development of new therapeutics and drugs are expected to boost further market expansion.
When the immune system attacks the healthy cells in the body mistakenly it is known as autoimmune disease. They attack parts such as joints or skin by releasing antibodies that attack the healthy cells. In some cases, only one organ gets attacked by autoimmune diseases whereas in other cases the whole body gets affected by autoimmune diseases. It is not possible to cure the autoimmune disease permanently; however, the intense response by the immune system can be treated and controlled by reducing the inflammation and pain.
The market is expected to grow due to increasing cases of autoimmune diseases. As per the statistics reported by the National Institute of Health (NIH), in the US alone, approximately 23.5 individuals are suffering from autoimmune diseases. Another report by RheumatoidArthritis.org suggests that about 1.3 million Americans are suffering from rheumatoid arthritis and the cases are increasing every year at a rapid pace.
Market Trends, Drivers, Restraints, and Opportunities
- Advancement of diagnostic methods coupled with the development of treatment devices & procedures are key factors helping the market growth.
- Slow turnaround procedures associated with the diagnosis of autoimmune diseases is another key factor driving the market expansion.
- High cost of therapeutics for autoimmune diseases is anticipated to act as a restraining point that can hamper the market growth during the forecast period.
- Lack of medical insurance coverage and complex reimbursement policies across countries are expected to hinder the market growth during the forecast period.
- Increasing initiatives taken by the government along with pharmaceutical companies in order to enhance the research & development programs for the development of new drugs are projected to present key opportunities for the market expansion.
Scope of the Autoimmune Treatment Market Report
The report on the global autoimmune treatment market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Autoimmune Treatment Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast |
|
Base Year |
2020 |
|
Historic Data |
2018–2019 |
|
Forecast Period |
2021–2028 |
|
Segmentation |
Applications (Systemic Autoimmune Diseases [Psoriasis, Rheumatoid Arthritis, Lupus, and Others] and Localized Autoimmune Diseases [Multiple Sclerosis]) and Products (Drugs, Diagnostic Equipment, and Therapeutic & Monitoring Equipment) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Bristol-Myers Squibb Co.; Amgen; Eli Lilly & Co.; Johnson & Johnson; Pfizer; AstraZeneca PLC; Roche; and Abbott Laboratories |
Autoimmune Treatment Market Segment Insights
Systemic autoimmune diseases segment is anticipated to dominate the market
On the basis of applications, the global autoimmune treatment market is bifurcated into systemic autoimmune diseases and localized autoimmune diseases. The systemic autoimmune diseases segment is further divided into psoriasis, rheumatoid arthritis, lupus, and others while the localized autoimmune diseases segment consists of multiple sclerosis. The systemic autoimmune diseases segment is anticipated to dominate the market in the coming years owing to the increasing incidence of rheumatoid arthritis and increasing awareness level among the patients.
Drugs segment is expected to expand at a substantial rate
Based on products, the market is divided into drugs, diagnostic equipment, and therapeutic & monitoring equipment. The drugs segment is expected to expand at a substantial rate during the forecast period attributed to the fact that all the autoimmune diseases have chronic nature cannot be cured permanently and require treatment with drugs. Some of the most commonly used drugs include hydroxychloroquine, glucocorticoids, anthralin, methotrexate, avonex, and non-steroidal anti-inflammatory drugs.
Asia Pacific market is estimated to exhibit considerable growth
In terms of regions, the global autoimmune treatment market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America dominated the market in 2019 and is projected to hold a major market share in the coming years due to the presence of a high population base being affected with autoimmune diseases along with the presence of high disposable income in the region. However, the market of Asia Pacific is estimated to exhibit considerable growth during the forecast period attributed to the improvement of healthcare infrastructure at a rapid pace coupled with the growing level of awareness among the patients related to the early diagnosis & treatment of autoimmune diseases.
Segments
The global autoimmune treatment market has been segmented on the basis of
Applications
- Systemic Autoimmune Diseases
- Psoriasis
- Rheumatoid Arthritis
- Lupus
- Others
- Localized Autoimmune Diseases
- Multiple Sclerosis
Products
- Drugs
- Diagnostic Equipments
- Therapeutic & Monitoring Equipments
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Bristol-Myers Squibb Co.
- Amgen
- Eli Lilly & Co.
- Johnson & Johnson
- Pfizer
- AstraZeneca PLC
- Roche
- Abbott Laboratories
Competitive Landscape
Key players competing in the global autoimmune treatment market are Bristol-Myers Squibb Co.; Amgen; Eli Lilly & Co.; Johnson & Johnson; Pfizer; AstraZeneca PLC; Roche; and Abbott Laboratories. Many of these players have adopted business strategies such as development of novel drugs, launch of new products, advancement of technologies, partnerships, mergers, and production capacity expansion in order to increase their expansion, their consumer base, and market position globally.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Autoimmune Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Autoimmune Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Autoimmune Treatment Market - Supply Chain
4.5. Global Autoimmune Treatment Market Forecast
4.5.1. Autoimmune Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Autoimmune Treatment Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Autoimmune Treatment Market Absolute $ Opportunity
5. Global Autoimmune Treatment Market Analysis and Forecast by Applications
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Applications
5.2.2. Y-o-Y Growth Projections by Applications
5.3. Autoimmune Treatment Market Size and Volume Forecast by Applications
5.3.1. Systemic Autoimmune Diseases Localized Autoimmune Diseases
5.4. Absolute $ Opportunity Assessment by Applications
5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Autoimmune Treatment Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Autoimmune Treatment Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Autoimmune Treatment Demand Share Forecast, 2019-2026
7. North America Autoimmune Treatment Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Autoimmune Treatment Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Autoimmune Treatment Market Size and Volume Forecast by Applications
7.4.1. Systemic Autoimmune Diseases Localized Autoimmune Diseases
7.5. Basis Point Share (BPS) Analysis by Applications
7.6. Y-o-Y Growth Projections by Applications
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Autoimmune Treatment Demand Share Forecast, 2019-2026
8. Latin America Autoimmune Treatment Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Autoimmune Treatment Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Autoimmune Treatment Market Size and Volume Forecast by Applications
8.4.1. Systemic Autoimmune Diseases Localized Autoimmune Diseases
8.5. Basis Point Share (BPS) Analysis by Applications
8.6. Y-o-Y Growth Projections by Applications
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Autoimmune Treatment Demand Share Forecast, 2019-2026
9. Europe Autoimmune Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Autoimmune Treatment Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Autoimmune Treatment Market Size and Volume Forecast by Applications
9.4.1. Systemic Autoimmune Diseases Localized Autoimmune Diseases
9.5. Basis Point Share (BPS) Analysis by Applications
9.6. Y-o-Y Growth Projections by Applications
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Autoimmune Treatment Demand Share Forecast, 2019-2026
10. Asia Pacific Autoimmune Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Autoimmune Treatment Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Autoimmune Treatment Market Size and Volume Forecast by Applications
10.4.1. Systemic Autoimmune Diseases Localized Autoimmune Diseases
10.5. Basis Point Share (BPS) Analysis by Applications
10.6. Y-o-Y Growth Projections by Applications
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Autoimmune Treatment Demand Share Forecast, 2019-2026
11. Middle East & Africa Autoimmune Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Autoimmune Treatment Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Autoimmune Treatment Market Size and Volume Forecast by Applications
11.4.1. Systemic Autoimmune Diseases Localized Autoimmune Diseases
11.5. Basis Point Share (BPS) Analysis by Applications
11.6. Y-o-Y Growth Projections by Applications
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Autoimmune Treatment Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Autoimmune Treatment Market: Market Share Analysis
12.2. Autoimmune Treatment Distributors and Customers
12.3. Autoimmune Treatment Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Bristol-Myers Squibb Co. Amgen Eli Lilly & Co. Johnson & Johnson Pfizer AstraZeneca PLC
2. Assumptions and Acronyms Used
3. Research Methodology
4. Autoimmune Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Autoimmune Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Autoimmune Treatment Market - Supply Chain
4.5. Global Autoimmune Treatment Market Forecast
4.5.1. Autoimmune Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Autoimmune Treatment Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Autoimmune Treatment Market Absolute $ Opportunity
5. Global Autoimmune Treatment Market Analysis and Forecast by Applications
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Applications
5.2.2. Y-o-Y Growth Projections by Applications
5.3. Autoimmune Treatment Market Size and Volume Forecast by Applications
5.3.1. Systemic Autoimmune Diseases Localized Autoimmune Diseases
5.4. Absolute $ Opportunity Assessment by Applications
5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Autoimmune Treatment Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Autoimmune Treatment Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Autoimmune Treatment Demand Share Forecast, 2019-2026
7. North America Autoimmune Treatment Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Autoimmune Treatment Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Autoimmune Treatment Market Size and Volume Forecast by Applications
7.4.1. Systemic Autoimmune Diseases Localized Autoimmune Diseases
7.5. Basis Point Share (BPS) Analysis by Applications
7.6. Y-o-Y Growth Projections by Applications
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Autoimmune Treatment Demand Share Forecast, 2019-2026
8. Latin America Autoimmune Treatment Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Autoimmune Treatment Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Autoimmune Treatment Market Size and Volume Forecast by Applications
8.4.1. Systemic Autoimmune Diseases Localized Autoimmune Diseases
8.5. Basis Point Share (BPS) Analysis by Applications
8.6. Y-o-Y Growth Projections by Applications
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Autoimmune Treatment Demand Share Forecast, 2019-2026
9. Europe Autoimmune Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Autoimmune Treatment Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Autoimmune Treatment Market Size and Volume Forecast by Applications
9.4.1. Systemic Autoimmune Diseases Localized Autoimmune Diseases
9.5. Basis Point Share (BPS) Analysis by Applications
9.6. Y-o-Y Growth Projections by Applications
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Autoimmune Treatment Demand Share Forecast, 2019-2026
10. Asia Pacific Autoimmune Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Autoimmune Treatment Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Autoimmune Treatment Market Size and Volume Forecast by Applications
10.4.1. Systemic Autoimmune Diseases Localized Autoimmune Diseases
10.5. Basis Point Share (BPS) Analysis by Applications
10.6. Y-o-Y Growth Projections by Applications
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Autoimmune Treatment Demand Share Forecast, 2019-2026
11. Middle East & Africa Autoimmune Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Autoimmune Treatment Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Autoimmune Treatment Market Size and Volume Forecast by Applications
11.4.1. Systemic Autoimmune Diseases Localized Autoimmune Diseases
11.5. Basis Point Share (BPS) Analysis by Applications
11.6. Y-o-Y Growth Projections by Applications
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Autoimmune Treatment Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Autoimmune Treatment Market: Market Share Analysis
12.2. Autoimmune Treatment Distributors and Customers
12.3. Autoimmune Treatment Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Bristol-Myers Squibb Co. Amgen Eli Lilly & Co. Johnson & Johnson Pfizer AstraZeneca PLC
Our Clients
Related Reports
Some other reports from this category!
